Epiomic Epidemiology Series: Benign Prostatic Hypertrophy Forecast in 17 Major Markets 2016-2026

February 2016 | 48 pages | ID: E0B443DBB6EEN
Black Swan Analysis limited

Abstracts

Benign Prostatic Hypertrophy (BPH) is a noncancerous (benign) enlargement of the prostate gland that can make urination difficult. The precise cause is not known but most likely involves changes caused by hormones, including testosterone and especially androgen dihydrotestosterone.

The prostate enlarges over time and is regarded as a normal aging process, with BPH being found to be common in males over the age of 60. However, if it is left untreated symptoms may worsen and the risks of urinary tract infections (UTIs) and acute urinary retention becomes higher and may require corrective surgery.

This report provides the current male prevalent population for BPH across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Sweden, Canada, Australia, Denmark, South Korea, Netherlands and China) split by 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of BPH have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for BPH include:

• Acute urinary retention (AUR)
• Recurrent UTIs
• Hydronephrosis
• Renal failure
• Prostate cancer

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global BPH’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of BPH and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on BPH’s prevalent population.
• Identify sub-populations within BPH which require treatment.
• Gain an understanding of the specific markets that have the largest number of BPH patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions /Features Associated with the Disease
Methodology for Quantification of Patient Numbers
  Additional data available on request
Top-Line Prevalence for Benign Prostatic Hypertrophy
Features of Clinically Diagnosed BPH Patients
  Severity and Frequency of Symptoms in BPH
  Urinary Incontinence and Retention in BPH
  Bladder Emptying and Obstructions
  Associated Co-morbid Conditions of BPH
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Figures

LIST OF FIGURES

Prevalence of clinically relevant (symptomatic) BPH by age across the 17 major markets in 2016
Breakdown by country of clinically relevant BPH patients in 2016

List Of Tables

LIST OF TABLES

IPSS questionnaire for suspected BPH patients
IPSS scoring and severity
Total prevalence of BPH, males (000s)
Prevalence of clinically relevant BPH, males (000s)
IPSS severity of clinically relevant BPH patients, males (000s)
Frequency of night-time urination in clinically relevant BPH patients, males (000s)
Frequency of urinary leakage in clinically relevant BPH patients, males (000s)
Urge incontinence in clinically relevant BPH patients, (000s)
AUR with moderate / severe symptoms in clinically relevant BPH patients, (000s)
Possible bladder outlet obstruction in clinically relevant BPH patients, males (000s)
Incomplete bladder emptying in clinically relevant BPH patients, males (000s)
Erectile dysfunction in clinically relevant BPH patients, males (000s)
Prostate cancer in clinically relevant BPH patients, males (000s)
Abbreviations and acronyms used in the report
USA Prevalence of BPH disease by 5-yr age cohort, males (000s)
France Prevalence of BPH disease by 5-yr age cohort, males (000s)
Germany Prevalence of BPH disease by 5-yr age cohort, males (000s)
Italy Prevalence of BPH disease by 5-yr age cohort, males (000s)
Spain Prevalence of BPH disease by 5-yr age cohort, males (000s)
United Kingdom Prevalence of BPH disease by 5-yr age cohort, males (000s)
Brazil Prevalence of BPH disease by 5-yr age cohort, males (000s)
Japan Prevalence of BPH disease by 5-yr age cohort, males (000s)
India Prevalence of BPH disease by 5-yr age cohort, males (000s)
Turkey Prevalence of BPH disease by 5-yr age cohort, males (000s)
Sweden Prevalence of BPH disease by 5-yr age cohort, males (000s)
Canada Prevalence of BPH disease by 5-yr age cohort, males (000s)
Australia Prevalence of BPH disease by 5-yr age cohort, males (000s)
Denmark Prevalence of BPH disease by 5-yr age cohort, males (000s)
South Korea Prevalence of BPH disease by 5-yr age cohort, males (000s)
Netherlands Prevalence of BPH disease by 5-yr age cohort, males (000s)
China Prevalence of BPH disease by 5-yr age cohort, males (000s)